Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons with differential pain etiology - PubMed
2 days ago
- #Suzetrigine
- #NaV1.8
- #Neuropathic Pain
- Suzetrigine (VX-548) is a selective NaV1.8 inhibitor with FDA approval for acute pain treatment.
- It shows activity-dependent effects on human dorsal root ganglion neurons, abolishing spontaneous discharges linked to neuropathic pain.
- Suzetrigine has moderate effects on evoked discharges, suggesting efficacy against spontaneous pain but less impact on breakthrough pain.
- The study involved human neurons from surgical patients and organ donors, tested in parallel electrophysiology studies.
- Nonselective VGSC antagonists have systemic toxicity risks, while selective inhibitors like suzetrigine target peripheral neurons to mitigate these risks.